-
FDA-Approved Peptide Therapies Offer New Options for Weight Management
The FDA has approved several peptide-based medications for weight management, giving patients and doctors more evidence-backed tools to address obesity and related health concerns.
-
Peptide-Based Weight Loss Treatments Continue to Gain FDA Recognition
The FDA’s growing acceptance of peptide-based therapies for weight management reflects years of clinical research and signals expanded options for patients working with their doctors on metabolic health.
-
FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management
Peptide-based medications continue to gain regulatory traction as tools for weight management, reflecting growing confidence in this class of therapies among health authorities.
-
Educators Spotlight Peptide Therapy’s Growing Role in Podiatric Care
A new educational resource from HMP Global Learning Network outlines how peptide therapy may support podiatrists in treating lower extremity conditions, reflecting growing interest in peptides within specialized medical fields.
-
New Clinical Trial Launches for Investigational Peptide Treatment of Rare Bone Disorder JMC
A new clinical trial is testing PTH-IA, an investigational peptide designed to target the root cause of Jansen’s Metaphyseal Chondrodysplasia, an ultra-rare disease with no currently approved treatments.
-
New Clinical Trial Explores Ziltivekimab for Heart Failure Patients with Inflammation
A new placebo-controlled study is investigating whether the peptide-based medicine ziltivekimab can help people living with heart failure and elevated inflammation. The trial reflects growing scientific interest in targeting inflammation as part of heart failure care.
-
New Phase III Trial Explores Enhanced Immunotherapy Combinations for Advanced Hodgkin Lymphoma
A phase III clinical trial is investigating whether adding nivolumab or brentuximab vedotin to standard chemotherapy can improve outcomes for patients newly diagnosed with stage III-IV classic Hodgkin lymphoma. The study represents a promising step toward more targeted, immune-based treatment options.
-
Retatrutide: 5 Promising Facts About the Next-Generation Weight-Loss Peptide
Retatrutide, a triple-hormone-receptor agonist peptide, is generating excitement for its potential to significantly advance obesity and metabolic treatment. Here’s what the growing buzz is really about.
-
FDA-Approved Peptide Therapies Offer New Options for Weight Management
Several peptide-based medications have received FDA approval for weight management, giving patients and doctors more evidence-backed tools to address obesity. These approvals reflect growing confidence in peptide science as a legitimate avenue for metabolic health.
-
Retatrutide Shows Impressive Weight Loss Results in Patients with Obesity and Type 2 Diabetes
New clinical trial data reveals retatrutide achieved weight loss of up to 20.8% in participants with both obesity and type 2 diabetes, marking a significant advancement in combination metabolic treatment.